Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis

Digestive Diseases and Sciences

Volumn 56, Issue 12, 2011, Pages 3638-3647

  Yasui, Shin ^a   Fujiwara, Keiichi ^a   Tawada, Akinobu ^a   Fukuda, Yoshihiro ^a   Nakano, Masayuki ^b   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Tokyo Women s Medical University   (Japan)

Author keywords

Acute onset; Autoimmune hepatitis; Disease severity; Intravenous glycyrrhizin

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; GLYCYRRHIZIC ACID; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PREDNISOLONE; URSODEOXYCHOLIC ACID; ANTIINFLAMMATORY AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; TREATMENT DURATION; TREATMENT RESPONSE; ACUTE DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; FOLLOW UP; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLYCYRRHIZIC ACID; HEPATITIS, AUTOIMMUNE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856151699     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1789-5     Document Type: Article

References (37)

1. Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820-833.
2. Mistilis SP, Skyring AP, Blackburn CRB. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Australas Ann Med. 1968;17:214-223.
3. Czaja AJ, Davis GL, Ludwig J, et al. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology. 1983;85:713-717. (Pubitemid 13033133)
4. Crapper RM, Bhathal PS, Mackay IR, et al. ''Acute'' autoimmune hepatitis. Digestion. 1986;34:216-225.
5. Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol. 1989;11:303-307. (Pubitemid 19147259)
6. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21:866-871. (Pubitemid 24374156)
7. Porta G, Da Costa Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Ped Gastroenterol Nutrition. 1990;11: 138-140. (Pubitemid 20203908)
8. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938. (Pubitemid 29514229)
9. Yamamoto S, Maekawa Y, Imamura M, et al. Treatment of hepatitis with antiallergic drug, Stronger Neo-Minophagen C. Clin Med Pediatr. 1958;13:73.
10. Suzuki H, Ohta T, Takino T, et al. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Double-blind trial. Asian Med J. 1983;26:423-438. (Pubitemid 14210247)
11. Hino K, Miyakawa H, Kondo T, et al. Effects of glycyrrhizin therapy on liver histology in chronic aggressive hepatitis. In: Shikata T, Porcell RH, Uchida T, eds. Viral hepatitis C, D and E. Amsterdam: Excerpta Medica; 1987:295-303.
12. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513-1520. (Pubitemid 24166476)
13. Iino S, Tango T, Matsushima T, et al. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol Res. 2001;19:31-40. (Pubitemid 32014110)
14. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26:664-669. (Pubitemid 27392358)
15. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified diagnostic criteria for autoimmune hepatitis. Hepatology. 2008;48:169-176. (Pubitemid 351975541)
16. Fujiwara K, Yasui S, Tawada A, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute onset autoimmune hepatitis. Liver Int. (Epub ahead of print). doi:10.1111/j.1478-3231. 2011.02524.x
17. Finney RS, Somers GF. The antiinflammatory activity of glycyrrhetinic acid and derivatives. J Pharm Pharmacol. 1958;10:613-620.
18. Doll R, Hill ID, Hutton C, et al. Clinical trial of a triterpenoid liquorice compound in gastric and duodenal ulcer. Lancet II. 1962;793-796.
19. Pompei R, Flore O, Marccialis MA, et al. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature. 1979; 281:689-690. (Pubitemid 10249050)
20. Crance JM, Lévêque F, Biziagos E, et al. Studies on the mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Res. 1994;23:63-76. (Pubitemid 24021216)
21. van Rossum TG, Vulto AG, de Man RA, et al. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther. 1998;12:199-205. (Pubitemid 28160013)
22. Yang BS, Ma YJ, Wang Y, et al. Protective effect and mechanism of stronger neo-minophagen C against fulminant hepatic failure. World J Gastroenterol. 2007;13:462-466. (Pubitemid 46178985)
23. Ikeda T, Abe K, Kuroda N, et al. The inhibition of apoptosis by glycyrrhizin in hepatic injury induced by injection of lipopolysaccharide/ D-galactosamine in mice. Arch Histol Cytol. 2008;71: 163-178.
24. Tsubota A, Kumada H, Arase Y, et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 1999;11:1077-1083. (Pubitemid 30433756)
25. Zhang L, Wang B. Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B. Hepatol Res. 2002;24:220.
26. van Rossum TG, Vulto AG, Hop WC, et al. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol. 2001;96:2432-2437. (Pubitemid 32769207)
27. Fujiwara K, Mochida S, Matsui A, et al. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646-657. (Pubitemid 351784977)
28. Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute onset autoimmune hepatitis. J Gastroenterol. 2008;43:951-958.
29. Yasui S, Fujiwara K, Yonemitsu Y, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011;46:378-390.
30. Fujiwara K, Nakano M, Yasui S, et al. Advanced histology and impaired liver regeneration are associated with disease severity in acute onset autoimmune hepatitis. Histopathology. 2011;58:693-704.
31. Fujiwara K, Yasui S, Tawada A, et al. Autoimmune fulminant liver failure in adults. A single Japanese center experience. Hepatol Res. 2011;41:133-141.
32. Yasui S, Fujiwara K, Yokosuka O. Autoimmune fulminant hepatic failure in chronic hepatitis C during peg-interferon-alfa 2b plus ribavirin treatment showing histological heterogeneity. Dig Liver Dis. (Epub ahead of print). doi:10.1016/j.dld.2011. 02.014
33. Fujiwara K, Yasui S, Yokosuka O. Efforts at making the diagnosis of acute onset AIH. Hepatology. (Epub ahead of print). doi: 10.1002/hep.24331
34. Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: summary of a workshop. Hepatology. 2008;47:1401-1415. (Pubitemid 351547926)
35. Williams R, Wendon J. Indications for orthotopic liver transplantation in fulminant liver failure. Hepatology. 1994;20:S5-S10.
36. Acharya SK, Dasarathy S, Tandon A, et al. A preliminary open trial on interferon stimulator (SNMC) derived from Glycyrrhiza glabra in the treatment of subacute hepatic failure. Indian J Med Res. 1993;98:69-74. (Pubitemid 23251628)
37. Tandon A, Tandon BN, Bhujwala RA. Clinical spectrum of acute sporadic hepatitis E and possible benefit of glycyrrhizin therapy. Hepatol Res. 2002;23:55-61. (Pubitemid 36113469)